Review
ADHD in adults
In: Therapeutics Letter. Vancouver (BC): Therapeutics Initiative; 1994. Letter 144.
2023 Sep.
- PMID: 39432701
- Bookshelf ID: NBK608180
Item in Clipboard
Review
ADHD in adults
No abstract available
Copyright © 1994 - 2022 Therapeutics Initiative, University of British Columbia.
Sections
- Summary and Conclusions
- Overdiagnosis and overtreatment in children
- How common is adult ADHD?
- How reliable is diagnosis?
- Pharmacotherapy with stimulants and atomoxetine
- Why treat adult ADHD?
- Evidence for pharmacotherapy from short-term RCTs in adults
- Evidence from observational studies
- Do ADHD medications affect substance use disorders?
- Evidence also limited for non-drug treatments
- Is lisdexamfetamine better than other stimulants?
- References
References
-
- Coey SH. Takeda accentuates the positives for adult ADHD patients in new ‘V is for Vyvanse’ campaign. Fierce Pharma September 17, 2020. https://www.fiercepharma.com/marketing/takeda-targets-adult-adhd-patient...
-
- Takeda Pharmaceuticals U.S.A. Inc. Takeda USA website. https://vyvanse.com/
-
- Therapeutics Initiative. What is the evidence for using CNS stimulants to treat ADHD in children? Therapeutics Letter 69 (Mar–May 2008). https://ti.ubc.ca/letter69
-
- Therapeutics Initiative. Atomoxetine for ADHD in children and adolescents. Therapeutics Letter 73 (Jan–Mar 2009). https://ti.ubc.ca/letter73
Publication types
LinkOut - more resources
Full Text Sources
